Evaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use

References

• Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38:203–215.
   PubMedGoogle Scholar
• Lenz W. A personal perspective on the thalidomide tragedy. Teratology. 1992;46:417–418.
   PubMedGoogle Scholar
• Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962;1:45.
   Web of Science ®Google Scholar
• McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358.
   Web of Science ®Google Scholar
• Casal JJ, Bollini M, Lombardo ME, et al. Thalidomide analogues: tumor necrosis factor-alpha inhibitors and their evaluation as anti-inflammatory agents. Eur J Pharm Sci. 2016;83:114–119.
   PubMed Web of Science ®Google Scholar
• Sedlarikova L, Kubiczkova L, Sevcikova S, et al. Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012;36:1218–1224.
   PubMed Web of Science ®Google Scholar
• Chaulet C, Croix C, Alagille D, et al. Design, synthesis and biological evaluation of new thalidomide analogues as TNF-alpha and IL-6 production inhibitors. Bioorg Med Chem Lett. 2011;21:1019–1022.
   PubMed Web of Science ®Google Scholar
• Montana JG, Buckley GM, Cooper N, et al. Aryl sulfonamides as selective PDE4 inhibitors. Bioorg Med Chem Lett. 1998;8:2635–2640.
   PubMed Web of Science ®Google Scholar
• Lima LM, Castro P, Machado AL, et al. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem. 2002;10:3067–3073.
   PubMed Web of Science ®Google Scholar
• Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidoimide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9:1625–1630.
   PubMed Web of Science ®Google Scholar
• Yeung SY, Kampmann S, Stubbs KA, et al. Novel thalidomide analogues with potent NF kappa B and TNF expression inhibition. MedChemComm. 2011;2:1073–1078.
   Web of Science ®Google Scholar
• Miyachi H, Koiso Y, Shirai R, et al. Tumor necrosis factor-alpha production enhancing activity of substituted 3ʹ-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity. Chem Pharm Bull. 1998;46:1165–1168.
   PubMed Web of Science ®Google Scholar
• Muller GW, Shire MG, Wong LM, et al. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998;8:2669–2674.
   PubMed Web of Science ®Google Scholar
• Da Silva YKC, Augusto CV, Barbosa MLD, et al. Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorg Med Chem. 2010;18:5007–5015.
   PubMed Web of Science ®Google Scholar
• Stewart SG, Spagnolo D, Polomska ME, et al. Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling. Bioorg Med Chem Lett. 2007;17:5819–5824.
   PubMed Web of Science ®Google Scholar
• Zhu XX, Giordano T, Yu QS, et al. Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem. 2003;46:5222–5229.
   PubMed Web of Science ®Google Scholar
• Machado AL, Lima LM, Araujo JX, et al. Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorg Med Chem Lett. 2005;15:1169–1172.
   PubMed Web of Science ®Google Scholar
• Luo WM, Yu QS, Salcedo I, et al. Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-alpha inhibitory activity. Bioorg Med Chem. 2011;19:3965–3972.
   PubMed Web of Science ®Google Scholar
• Takeuchi Y, Shiragami T, Kimura K, et al. (R)- and (S)-3-fluorothalidomides: isosteric analogues of thalidomide. Org Lett. 1999;1:1571–1573.
   Web of Science ®Google Scholar
• Man HW, Corral LG, Stirling DI, et al. alpha-fluoro-substituted thalidomide analogues. Bioorg Med Chem Lett. 2003;13:3415–3417.
   PubMed Web of Science ®Google Scholar
• Chung F, Palmer BD, Muller GW, et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Oncol Res. 2003;14:75–82.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mark TM, Lacy MQ. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol. 2013;88:S36–S44.
   PubMed Web of Science ®Google Scholar
• Dalgleish A, Galustian C. The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol. 2010;6:1479–1484.
   PubMed Web of Science ®Google Scholar
• Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013;32:4191–4202.
   PubMed Web of Science ®Google Scholar
• REVLIMID®. (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma. Jul 15, 2016 Summit, NJ, USA: Celgene Corporation, Press release. Available at. http://ir.celgene.com/releasedetail.cfm?ReleaseID=979705 [Last accessed 21 October 2016.
   Google Scholar
• Sherbet GV. Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. Anticancer Res. 2015;35:5767–5772.
   PubMed Web of Science ®Google Scholar
• Pan BQ, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012;136:56–68.
   PubMed Web of Science ®Google Scholar
• Celgene Reports Fourth Quarter and Full Year. Operating and Financial Results. Jan 28, 2016 Summit, NJ, USA: Celgene Corporation, Press release. Available at. http://ir.celgene.com/releasedetail.cfm?ReleaseID=952157 Last accessed 21 October 2016.
   Google Scholar
• World’s Top Ten Cancer Drugs by 2020. Igea, The Hub for Medicine, Pharma and Health. Available at: https://igeahub.com/2016/04/01/worlds-top-ten-cancer-drugs-by-2020/. [Last accessed 21 October 2016]
   Google Scholar
• IMIDS. Celgene Corporation, USA, Summit, NJ, USA. Available at: http://www.celgene.com/research-development/medical-innovation/imids/. [Last accessed 21 October 2016]
   Google Scholar
• An Investor’s Crash Course on Celgene Corporation. The Market Realist. Available at: http://marketrealist.com/2015/08/investors-crash-course-celgene/. [ Last accessed 21 October 2016]
   Google Scholar
• Celgene Corporation, Summit, NJ, USA. Preparation of 2-(2,6-dioxo-3-piperidinyl)-1-oxo- and 1,3-dioxoisoindolines as TNFα inhibitors patent WO2009145899 (2009).
   Google Scholar
• Burkhard JA, Wuitschik G, Plancher JM, et al. Synthesis and Stability of Oxetane Analogs of Thalidomide and Lenalidomide. Org Lett. 2013;15:4312–4315.
   PubMed Web of Science ®Google Scholar
• Walz S, Weis S, Franz M, et al. Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. Electrophoresis. 2015;36:796–804.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Naziruddin S, et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006;30:849–858.
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34(+) progenitor cells. Cancer Res. 2007;67:746–755.
   PubMed Web of Science ®Google Scholar
• Ruchelman AL, Man HW, Zhang WH, et al. Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity. Bioorg Med Chem Lett. 2013;23:360–365.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Mendy D, Parton A, et al. CC-122 Is a novel pleiotropic pathway modifier with potent in vitro immunomodulatory and anti-angiogenic properties and in vivo anti-tumor activity in hematological cancers. Blood. 2012;120:2963.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation, Summit, NJ, USA. Preparation of aminoalkyl-N-(dioxopiperidinyl)isoindolinone derivatives for use as antitumor agents. Vol. WO2008027542 (2008).
   Google Scholar
• Celgene Corporation, Summit, NJ, USA. Preparation of piperidinyl isoindolinone derivatives with antiproliferative activity for cancer therapy. WO2016007848 (2016).
   Google Scholar
• Raval G, Mehta P. TNF-α inhibitors: are they carcinogenic. Drug Healthc Patient Saf. 2010;2:241–247.
   PubMedGoogle Scholar
• Matyskiela ME, Lu G, Ito T, et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature. 2016;535:252–257.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–1350.
   PubMed Web of Science ®Google Scholar
• Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803–809.
   PubMed Web of Science ®Google Scholar
• Bhogaraju S, Dikic I. A peek into the atomic details of thalidomide’s clinical effects. Nat Struct Mol Biol. 2014;21:739–740.
   PubMed Web of Science ®Google Scholar